Nosocomial Rotavirus Gastroenteritis in pediatric patients: a multi-center prospective cohort study by Festini, Filippo et al.
RESEARCH ARTICLE Open Access
Nosocomial Rotavirus Gastroenteritis in pediatric
patients: a multi-center prospective cohort study
Filippo Festini
1*, Priscilla Cocchi
1, Daniela Mambretti
2, Bruna Tagliabue
3, Milena Carotti
4, Daniele Ciofi
1,
Klaus P Biermann
5, Roberto Schiatti
5, Franco M Ruggeri
6, Fernando Maria De Benedictis
4, Alessandro Plebani
3,
Alfredo Guarino
2, Maurizio de Martino
1
Abstract
Background: Few data are available on the incidence of nosocomial Rotavirus infections (NRVI) in pediatric
hospitals and on their economic impact. The goals of this study were: to evaluate the incidence of NRVI in various
Italian pediatric wards during the course of two peak RV seasons; to investigate possible risk factors for NRVI; to
estimate the costs caused by NRVI.
Methods: prospective cohort study. Population: all the children under 30 months of age who were admitted
without any symptom or diagnosis of gastroenteritis in the pediatric hospitals of Florence, Naples, Brescia and
Ancona, Italy, during the winter-spring periods 2006-2007 and 2007-2008. Serial RV rapid tests and clinical
monitoring were carried out on the cohort. Telephone interviews were performed from 3 to 5 days after discharge.
Results: 520 out of 608 children completed the study (85.6%). The overall incidence of NRVI was 5.3% (CI95% 3.6-
7.5), (7.9 per 1,000 days of hospital stay, CI 95% 5.3-11.3). The average duration of hospital stay was significantly
longer for children who had NRVI (8.1 days, SD 5.4) than for non-infected children (6.4 days, SD 5.8, difference
1.7 days, p = 0.004). The risk of contracting NRVI increased significantly if the child stayed in hospital more than
5 days, RR = 2.8 (CI95% 1.3-6), p = 0.006. In Italy the costs caused by NRVI can be estimated at 8,019,155.44 Euro
per year. 2.7% of the children hospitalized with no gastroenteritis symptoms tested positive for RV.
Conclusions: Our study showed a relevant incidence of NRVI, which can increase the length of the children’s stay
in hospital. Limiting the number of nosocomial RV infections is important to improve patients’ safety as well as to
avoid additional health costs.
Background
Rotavirus (RV) is the most frequent cause of viral gas-
troenteritis in children under 5 years of age. The virus
can cause severe diarrhea and dehydration, especially in
children aged 6 to 24 months. In developing countries,
acute gastroenteritis due to RV infection (RV AGE)
causes the death of approximately 440,000 children
every year [1,2]. In the USA, RV is responsible for
the hospitalization of 58,000 to 70,000 children every
year [3].
The RV genus of the Reoviridae family is very diverse,
as it consists of different groups (A-G) and of different
types based on the characteristics of the surface proteins
VP7 (G = glycoprotein) and VP4 (P = protease-sensitive
protein). To date, at least 23 G types and 31 P types of
g r o u pAR V s ,t h eg r o u pw h i c hm o s tc o m m o n l yi n f e c t s
humans, have been differentiated [4,5].
The virus is mainly transmitted by feco-oral route or
by direct contact, but it can occasionally be transmitted
through droplets. Since the virus is stable in the envir-
onment, transmission can occur through the ingestion
of contaminated water and food, and through contact
with contaminated surfaces and objects. Cross-infection
through contamination of the hands is probably the
most common transmission route in healthcare settings.
RV AGE has an incubation period of 1 - 3 days, which
is followed by the sudden onset of watery diarrhea, with
possible dehydration, vomiting and fever lasting from 4
to 7 days. In the temperate zones of the planet, the
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from November to March), whereas in tropical regions
RV infections occur all year round [6].
In 2007 the World Health Organization recommended
the inclusion of rotavirus vaccination in the national
immunization programs of countries in which RV gastro-
enteritis has a substantial public health impact [7]. Evi-
dence of the effectiveness of immunization programs is
available for the two existing RV vaccines, both in indus-
trialized and in developing countries [8-10]. Recent data
suggest that the RV vaccine coverage is as high as 70% in
some USA states [11]. Reported RV vaccine coverage in
European countries varies from 35% to 85% [12].
In industrialized countries, RV infection is only rarely
a cause of death for children. Nevertheless, the high
number of hospitalizations due to RV indicates that the
economic and social impact of the disease deserves
attention [13].
In particular, RV infections contracted by hospitalized
children is a source of worry. In pediatric hospitals, the
reservoir of infection is represented by already infected
children, while the vehicle can be toys or other objects
which are handled by children, also via the hands of
mothers and health care workers which have not been
washed correctly. The infection contracted in the hospital
setting causes the child to stay longer in hospital as well as
additional economic and social costs [14]. Asymptomatic
RV infections are a particular cause of concern. These
infections lack the symptoms of vomiting and/or diarrhea,
or infected people often show nonspecific symptoms such
as fever, headache, nausea, and fatigue [15]. Recent studies
showed relevant prevalences of asymptomatic RV infec-
tions both among adults and children [15,16].
At present, the number of studies on the incidence of
nosocomial RV infections (NRVI) in pediatric hospitals
[16-26] and on their economic impact [14,16,27-29] is
limited.
The incidence of NRVI in hospitals may be underesti-
mated and little attention may be given to prevention
and to the increase in the social costs of the disease, e.g.
longer hospital stay (direct costs), as well as in absences
from work of family members who assist the young
patient (indirect costs) [30,31].
Additional data on the incidence of NRVI are useful
to evaluate the risks linked with healthcare, to plan the
use of available resources, and to estimate healthcare
costs [32,33].
To calculate the incidence of NRVI with acceptable
precision, it is necessary to carry out prospective popula-
tion studies including all the children hospitalized during
a period of reference. Given that the incubation period of
RV infection can vary from 24 to 72 hours and in order
to be able to detect all NRVI cases, tests on the feces of
all the patients hospitalized without gastroenteritis
symptoms should be carried out upon admittance, as
well as during the period of hospital stay if gastroenteritis
symptoms manifest themselves. Furthermore, all children
must be clinically monitored for up to 72 hours following
discharge from the hospital [16,34].
The primary objective of our study was to evaluate the
incidence of NRVI in various pediatric wards through-
out Italy during the course of two peak RV infection
periods.
The secondary objectives were:
- To investigate possible risk factors for NRVI among
the demographic and nosological characteristics of the
hospitalized children.
- To estimate the additional health costs caused by
nosocomial RV infections in the periods under
consideration.
Methods
Study design
We conducted a multi-center observational prospective
cohort study during two peak RV infection periods
(winter-spring 2006-2007, winter-spring 2007-2008).
The choice of the period was based on a preliminary
study, which showed that approximately 80% of NRVI
cases occur during the winter-spring period [35].
The incidence of nosocomial RV infection was investi-
gated by constantly monitoring the clinical conditions of
the whole population of children hospitalized in the par-
ticipating wards during the study period.
In the first period, the study was carried out in three
pediatric wards in two hospitals ("Meyer” Children’s
Hospital of Florence and Pediatric Unit of the University
of Naples “Federico II”). In the second period, the study
was carried out in five pediatric wards in four hospitals
(the ones previously mentioned, as well as the Pediatric
Unit of the Children’s Hospital of Brescia and the Pedia-
tric Unit of the “Salesi” Hospital of Ancona). The study
setting was represented by the wards which normally
care for children up to 30 months of age who do not
need intensive care.
Subjects were consecutively recruited from all the chil-
d r e nu n d e r3 0m o n t h so fa g ew h ow e r ea d m i t t e dt ot h e
participating wards without a diagnosis of RV AGE and
without any symptom suggesting gastroenteritis (diar-
rhea or vomiting with or without fever) in the periods
from 24/1/2007 to 31/5/2007 and from 14/12/2007 to
31/5/2008. Informed consent to participation in the
s t u d yw a sg i v e nb yt h ec h i l d r e n ’s parents. Recruitment
was performed upon hospital admission. Upon recruit-
ment of each child in the participating ward, medical
history data were obtained.
A rapid RV test was carried out on the first feces
emitted by all the recruited subjects after hospital
admittance, regardless of their clinical condition.
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fecal sample within 24 hours of hospital admission were
considered “lost to follow-up”. In this case, evidence
that the subject was negative for RV upon enrollment
and thus susceptible to infection was unavailable.
The children who tested positive for RV upon admit-
tance were considered not recruitable ex-post,a st h e y
did not meet one of the inclusion criteria.
Each of the enrolled children was visited by a doctor
or nurse (including physical examination) at least once a
day for the whole duration of their stay in hospital. The
pediatricians and nurses performed a clinical evaluation
and routine check-up on the children following the indi-
cations of the protocol adopted in the ward. When signs
and symptoms of gastroenteritis arose during hospital
stay, a RV test of the child’s feces was carried out.
The rapid RV test was performed again at the
moment of discharge from the hospital, irrespective of
the child’s clinical condition.
Furthermore, the family was contacted via telephone
between the 3
rd and the 5
th day following discharge to
answer a number of questions regarding the appearance
of signs and symptoms of gastroenteritis after leaving
the hospital ward.
The RV test was conducted using a rapid test for RV
(Vikia Rota-Adeno Biomerieux, Lyon, France). This test
has a 99% sensitivity rate and 100% specificity.
The samples which tested positive for RV were pre-
served at -20°C and later sent to the Istituto Superiore
di Sanità (National Institute of Health, Rome, Italy) for
genotyping.
The recruited subjects who tested negative for RV at
hospital admittance with the rapid test were considered
cases of nosocomial RV infection when the rapid test
indicated RV infection at least 72 hours after hospital
admittance.
Children were considered lost to follow-up in case of
withdrawal of consent by the parents, in case of inability
to obtain a fecal sample for RV control upon discharge
from the hospital, and in case of inability to carry out a
telephone interview within 3 to 5 days after discharge.
The study was conducted in accordance with the lat-
est amended version of the Declaration of Helsinki, with
the Good Clinical Practice guidelines and with the Eur-
opean guidelines on conducting clinical studies in pedia-
trics (CPMP/ICH/99). Authorization was requested and
obtained from the ethics committee of all the four hos-
pitals involved in the study.
Data Analysis
In order to calculate the incidence of NRVI, the
numerator is represented by the detected NRVI cases
(as previously defined); the denominator is represented
by the number of recruited subjects minus the ones lost
to follow up.
Afterward, we calculated the incidence per 1,000 days
of hospital stay. In this case, the numerator is repre-
sented by the number of detected NRVI cases (as pre-
viously defined); the denominator is represented by the
number of total days spent in hospital by the recruited
patients, minus the number of days of stay of the
patients lost to follow-up and of the ones with RV infec-
tion after admission.
The 95% confidence interval was calculated on the
incidence [36].
In order to explore any possible differences in the risk
of contracting NRVI based on the various characteristics
of the subjects, we carried out an exploratory statistical
analysis by stratifying the subjects on the basis of several
qualitative and quantitative variables.
The statistical analysis of the differences in the risk of
contracting NRVI for dichotomous variables (sex and
age range) was conducted by calculating the relative
risks and by determining the corresponding 95% confi-
dence interval.
We also studied the difference in age and in the
length of hospital stay of children with and without
NRVI. The statistical analysis was carried out by com-
paring the mean age using ANOVA and the length of
hospital stay with a non-parametric test (Mann-
Whitney).
In order to estimate the additional costs attributable
to NRVI, we first estimated the number of children
affected by NRVI in Italy in one year: this was done by
using the data concerning the hospitalization of children
provided by the Istituto Centrale di Statistica Italiano
(Italian Central Institute of Statistics) [37,38] and by
applying the incidence detected in our study to these
data.
For each additional day of hospital stay due to NRVI,
the following were calculated:
- the cost of the days spent in hospital, based on the
Diagnosis Related Groups [39-41] of the Italian Ministry
of Health;
- the cost of lost productivity due to absence from
work of one of the parents, on the basis of the data pro-
vided by the Italian Central Bank [42,43].
For each of the two study periods, the coordinating
center performed three data quality assessments by ana-
lyzing all of the clinical assessment forms and by verify-
ing data consistency. Random assessment of data
recording quality was also conducted.
Genotyping
The clinical RV isolates were shipped in dry ice to the
National Institute of Health of Rome for strain
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pared for further rotavirus-specific RT-PCR and nested
PCR tests. Nucleic acid extraction and G/P rotavirus
typing: double-stranded viral RNA was extracted from
140 ul of the 10% fecal suspension by using a commer-
cial kit (QIAamp viral RNA minikit; QIAGEN) and fol-
lowing the manufacturer’s instructions. The RNA was
eluted in 50 ul of RNase-free water and stored at -80°C.
G and P rotavirus genotyping was performed by using
RT-PCR methods, as reported previously [44]. In order
to identify the G type, we used the VP7-F and VP7-R
consensus primers [45] in RT-PCR. Subsequently, the
VP7-R primer was used in a nested multiplex PCR
together with G1, G2, G3, G4, G8, G9, and G10 type-
specific primers [44-46]. The samples which tested
negative by G typing with the primers described above
were also tested by using a PCR with G12-specific pri-
mers [47]. For P types, we used Con2-Con3 consensus
primers [48] in RT-PCR, followed by the standard mul-
tiplex PCR including the Con3, in combination with the
typing primers P4, P6, P8, P9, P10, and P11 [46,48,49].
VP6 RT-PCR was performed as described previously
[50].
Results
We were able to recruit 608 subjects who met the inclu-
sion criteria.
Out of the 625 subjects who initially met the inclusion
criteria, 17 (2.7%) tested positive for RV on the rapid
test conducted upon hospital admittance, even without
symptoms of AGE. 88 subjects were lost to follow-up
(equal to 14.4%), 64 of whom due to the inability to
take a stool sample within 24 hours of admittance and
another 24 due to the inability to perform a final evalua-
tion (faeces exam or telephone interview).
Figure 1 shows the flowchart of the subjects included
in the study.
The 520 children who completed the study had a
mean age of 9.4 months (SD 8.2) and stayed in hospital
for an average of 6.5 days (SD 5.8). 41.3% of them were
female. With respect to age, 11.3% of children were
newborns, 34.8% were aged from 1 to 6 months, 19.2%
from 7 to 12 months and 34.7% from 13 to 30 months.
Detection of NRVI
During the study period, 28 cases of NRVI were
detected. Sixteen NRVIs out of 229 subjects were
detected in the first season and 12 out of 291 in the sec-
ond season.
The total incidence of NRVI was 5.3% (CI95% 3.6-7.5),
6.9% in the first season (CI95% 4.1-10.8) and 4.1% in the
second season (CI95% 2.2-6.9).
The incidence per day of hospital stay was also calcu-
lated. The overall incidence of NRVI (per 1,000 days of
hospital stay) was 7.9‰ (CI95% 5.3-11.3): 11.5‰ in the
first season (CI95%6.6-18.7) and 6.1‰ in the second
season (3.2-10.8).
Based on the telephone interviews performed from 3
to 5 days after hospital discharge, 29 additional cases of
suspected gastroenteritis emerged after the subjects
returned home and were thus associated with being hos-
pitalized. However, it was not possible to obtain diag-
nostic confirmation of these cases with an RV test on
stools.
Table 1 shows the distribution of the reasons of hospi-
talization among the 28 children who had NRVI.
Statistical analysis
The risk of contracting NRVI for females was half the
one for males (3.7% vs. 6.5%). However, the difference is
not statistically significant (RR = 0.57, CI 0.25-1.27).
With respect to age, the incidence of NRVI was 4.23
(CI 95% 2.3-7.6) in children under 6 months of age (n =
236). In children aged 6 months or more (n = 284), the
incidence of NRVI was 6.33 (CI 95% 4-9.7), RR = 1.49,
CI 95% 0.7-3.1.
Figure 1 Flowchart of the subjects included in the study.
Table 1 Distribution of the reasons of hospitalization
among the 28 children who had NRVI
reason of admission n % reason of admission n %
pneumonia 8 28.6 gastro-oesophageal
reflux
1 3.6
bronchiolitis 1 3.6 pyelonefritis 2 7.1
acute problems in chronic
patients
1 3.6 failure to thrive 1 3.6
febrile seizure 2 7.1 trauma 1 3.6
anemia 3 10.7 other 7 25.0
non febrile seizure 1 3.6
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th month of age (n = 19) turned out
to be at a higher risk of contracting NRVI (21.1%) than
children of all other ages, RR 4.39, CI95% 1.69-11.4.
No statistically significant difference was found
between the mean ages of children with and without
NRVI (9.3 months and 9.4 months respectively, p = ns).
There was no statistically significant difference also
between the mean ages of children with and without
NRVI stratified by sex and season of study (1
st or 2
nd
season of the study).
Mean hospital stay resulted significantly longer (8.1
days, SD 5.4) for children who had NRVI (n = 28) than
f o rt h eo n e sw h od i dn o tc o n t r a c ti t( 6 . 4d a y s ,S D5 . 8 ,
difference of 1.7 days, p = 0.004) (n = 492). On average,
hospital stay was thus 26.5% longer for children who
had contracted the nosocomial infection.
Table 2 shows the difference between the mean length
of hospital stay for children with and without NRVI
stratified by sex and season.
Among children whose hospital stay was longer than 5
days (n = 225) there were 19 cases of NRVI vs 9 cases
among children with an hospital stay up to 5 day long
(n = 295), with a RR = 2.8 (CI95% 1.3-6), p = 0.006.
Among children admitted to hospital in the month of
March (n = 131) there were 12 cases of INRV vs 16
cases among children admitted in all other months (n =
389), with a RR of 2.2 (CI95%1.08-4.5), p = 0.02.
Cost analysis
In Italy approximately 885,000 children aged 0 to 14
require hospital admission every year. Approximately
414,000 of them are under 30 months of age, 36.9% of
whom are hospitalized during the period of reference of
our study (December-May) [37,38]. Therefore, the total
number of children under 30 months of age who are
hospitalized during the RV peak period is approximately
152,766.
Based on the incidence found in our study, one could
estimate that in Italy approximately 8,097 children
under 30 months of age hospitalized in the December-
March period contract NRVI every year.
Based on the differences we found in our study in the
length of hospital stay between the children affected and
the ones not affected by NRVI, the total increase in hos-
pital stay caused by NRVI can be estimated to be
13,764.9 days. The average cost of a day in hospital in
an Italian pediatric ward is 434.58 Euro [39-41], while
t h ea v e r a g eu n i t a r yc o s to fal o s td a yo fw o r ki s1 4 8 . 0 0
Euro [42,43].
At a national level, the additional health costs derived
from longer hospital stay due to NRVI can thus be esti-
mated to be 8,019,155.44 Euro per year.
The cost of one RV vaccination is 164 Euro. There-
fore, vaccinating all the subjects included in our study
would have cost 85,280 Euro. Based on the differences
we found in the length of hospital stay between the chil-
dren affected and the ones not affected by NRVI, we can
speculate that through RV vaccination, the total number
of days spent by children with NRVI in hospital (229
days) would have been reduced to 168.3. Saving 60.7
hospital days corresponds to an estimated reduction in
healthcare expenditure of 35,362.60 Euro per year.
Typing of collected isolates
The results of genotyping show that in winter the G1 P
[8] genotype is more common (80%, n = 12). Other gen-
otypes found during the winter season were G9 P[8]
(13.3%, n = 2) and G3 P[8] (6.6%, n = 1).
The distribution of the genotypes responsible for the
contraction of NRVI in spring is instead more varied:
G1 P[8] (50%, n = 6), G9 P[8] (41.6%, n = 5), G2 P[4]
( 8 . 3 % ,n=1 ) .I no n ec a s e ,i tw a sn o tp o s s i b l et ot y p e
the isolate.
Discussion
At present, several retrospective studies providing esti-
mates of the incidence of NRVI in children are available.
Compared to them, prospective cohort studies can pro-
vide more reliable and less biased data. However, to
date only few researches on the incidence of NRVI have
been conducted using a prospective cohort study design
and the existing ones were mainly carried out on small
populations [19-26].
Our results give an updated and representative picture
of the epidemiology of nosocomial RV infections, which
affect more than 5% of the children under 30 months of
age hospitalized in winter and in spring. This also con-
firms the clinical and social relevance of this type of
infection. The total incidence of NRVI detected in our
study deserves attention and it is consistent with the
results of other studies having the same design [19-26].
Table 2 Differences between the mean length of hospital
stay for children with and without NRVI stratified by sex
and season
Children with
NRVI
Children without
NRVI
p
Males 7.6
(sd 7.2)
n=2 0
6.2
(sd 8.3)
n = 286
0.03
Females 9.5
(sd 5.4)
n=8
6.7
(sd 6.1)
n = 206
0.03
1st season 7
(sd 2.6)
n=1 6
6.1
(sd 5.9)
n = 213
0.01
2nd season 9.6
(sd 7.6)
n=1 2
6.6
(sd 5.7)
n = 279
ns
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reports that NRVIs account for 0.3-27.7% of all hospital
admissions and for 1.6-15.8 per 1,000 days of hospital
stay [14].
A limit of our study could be the fact that the
observed cohort had a loss to follow-up of 14.4%, a sta-
tistically acceptable percentage which should not to be
overlooked, but which does not alter the reliability of
results.
Another possible limit of our study may be the fact
that no information is available about the percentage of
recruited children immunized against RV and about the
percentage of breast-fed babies among them. This infor-
mation could have given important indications on how
to evaluate the incidence of NRVI resulting from our
study. Breastfeeding is indeed associated with a reduced
incidence of gastroenteritis [51]. Our data show a
reduced incidence of NRVI in children under 6 months
of age, which might be explained both by breastfeeding
and by the presence in younger infants of transplacen-
tally transferred maternal anti-RV antibodies [52]. How-
ever, the difference is not statistically significant.
With respect to the possible risk factors for NRVI, the
mean age of the children affected by NRVI did not differ
from the one of children who were not. No significant
difference in the incidence of NRVI in the two genders
was found.
In line with the data of other studies [14], the period
of highest risk for NRVI turned out to be the month of
March. Our study also highlighted that the length of
hospital stay influences the risk of contracting NRVI. In
fact, the risk increases in a statistically significant man-
ner after the fifth day in hospital.
Our study also showed that NRVI brings about a sta-
tistically significant and clinically relevant increase in
hospitalizations, thus causing higher, non-negligible
costs for the healthcare and social systems, also in rela-
tion to the total healthcare costs of a country.
Our data do not seem to suggest a possible decrease
in the direct costs of hospitalization following RV vacci-
nation. However, our study population is limited and
additional research is necessary to evaluate the possible
impact of RV vaccination on the additional costs high-
lighted in our study.
With respect to typing isolates responsible for NRVI,
recent global epidemiology studies, used to monitor the
emergence of new strains, highlighted that 88% of the
strains which can infect human beings have G1, G2, G3
and G4 genotype in combination with P[8] or P[4] ele-
ments [53]. The results of our study are consistent with
these previous findings.
It is worth noting that the genotypes of the isolates
found in our study are all covered by the two existing
Rotavirus vaccines (Rotateq, Sanofi Pasteur MSD, Lyon
and Rotarix, GlaxoSmithKline Biologicals, Rixensart)
Since the transmission of RV occurs primarily by con-
tact, the results of our study confirm the importance of
insisting on handwashing, on the implementation of
appropriate hygiene standards and on prevention, as
recommended also in the existing guidelines [54-56] for
relatives of hospitalized children and for hospital staff.
It is noteworthy that 2.7% of the recruitable subjects
who were hospitalized for reasons other than gastroen-
teritis, and who had no gastroenteritis symptoms, tested
p o s i t i v ef o rR V .T h e s ec h i l d r e nc a nb e c o m eas o u r c eo f
outbreaks of NRVI within the ward where they are
admitted. Using the RV rapid test upon hospital admis-
sion during the period of higher risk of NRVI for chil-
dren under 30 months of age might be a way to reduce
the impact of NRVI in pediatric hospitals. However,
additional studies are needed to confirm this hypothesis.
Conclusion
Nosocomial Rotavirus infection is an important problem
from a clinical, organizational and economic point of
view. Although RV is a marginal cause of death in Wes-
tern countries, limiting the number of nosocomial RV
infections is important both to improve patients’ safety
and to avoid additional health care costs.
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